Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 8/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.40 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4716513 | 0.89 | TGFBR1 (0.54) | TGFBR1 | |
| SCHEMBL4718766 | 0.84 | USP30 (0.42) | GPR119PTPN1NPC1RAB9ANAMPT | |
| SCHEMBL4714943 | 0.84 | NR1H2 (0.56) | GPR119PTPN1NPC1RAB9ANAMPT | |
| SCHEMBL4721313 | 0.84 | STS (0.46) | NAMPTALDH1A1ESR2NR1H2 | |
| SCHEMBL4718638 | 0.82 | TGFBR1 (0.44) | GPR119PTPN1NPC1RAB9ATGFBR1 | |
| SCHEMBL4789781 | 0.78 | ESR2 (0.66) | GPR119PTPN1NPC1RAB9ANAMPT | |
| SCHEMBL5600152 | 0.78 | NR1H2 (0.65) | GPR119PTPN1NPC1RAB9ANAMPT | |
| SCHEMBL18423515 | 0.77 | PTPN1 (0.55) | GPR119PTPN1NPC1RAB9ANAMPT | |
| SCHEMBL4714918 | 0.77 | ALDH1A1 (0.39) | GPR119PTPN1NPC1RAB9ANAMPT | |
| SCHEMBL7017461 | 0.73 | NPC1 (0.58) | GPR119PTPN1NPC1RAB9AESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1216230-B1 | FUSED CYCLOHEPTANE AND FUSED AZACYCLOHEPTANE COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR ANTAGONISTS | AMGEN INC (US) | 2008-04-23 | — | — | EP | disclosed |
| US-6514964-B1 | Treating diseases, conditions or disorders mediated by integrin receptors, such as vitronectin and fibronectin receptors | AMGEN INC. | 2003-02-04 | — | — | US | disclosed |